Explore

Trendline Trendline
Apnimed Plans $160M IPO to Fund Launch of Sleep Apnea Drug Oxnimbi

Apnimed Plans $160M IPO to Fund Launch of Sleep Apnea Drug Oxnimbi

Apnimed Plans $160M IPO to Fund Launch of Sleep Apnea Drug Oxnimbi
TheStreet TheStreet
Goldman Sachs uncovers key AbbVie stock signals before earnings

Goldman Sachs uncovers key AbbVie stock signals before earnings

AbbVie(ABBV) reports second-quarter results on Friday, July 31, and the mood around the stock has changed. A few months ago, investors were restless. The two drugs carrying the company were doing fine, but everyone already knew that, and the market wanted a new reason to invest. Goldman Sachs went ...
Trendline Trendline
Alkermes Reports Break-Even Q2 Earnings, Revenue Surpasses Expectations

Alkermes Reports Break-Even Q2 Earnings, Revenue Surpasses Expectations

Alkermes Reports Break-Even Q2 Earnings, Revenue Surpasses Expectations
AP News AP News
Most of Wall Street rises as oil prices ease, even as chip stocks keep dropping

Most of Wall Street rises as oil prices ease, even as chip stocks keep dropping

Most U.S. stocks are rising after Coca-Cola and other companies reported stronger profits for the spring than analysts expected
Reuters Reuters
GSK raises margin outlook, plots $2.5 billion restructuring to fast-track new drugs

GSK raises margin outlook, plots $2.5 billion restructuring to fast-track new drugs

By Bhanvi Satija and Raechel Thankam Job LONDON, July 28 (Reuters) - GSK launched a £1.9 billion ($2.52 billion) cost-savings effort on Tuesday to help fund the British drugmaker's expanded late-stage study roster, as CEO Luke Miels works to deliver on his promise of faster drug development.
Reuters Reuters
Nasdaq futures slide as AI worries mount ahead of pivotal earnings

Nasdaq futures slide as AI worries mount ahead of pivotal earnings

By Johann M Cherian and Ragini Mathur July 28 (Reuters) - Nasdaq futures fell on Tuesday, mirroring a cautious mood across global markets toward AI chip stocks on concerns about hefty corporate spending and rising Chinese competition, ahead of earnings from some of the biggest companies on Wall
Trendline Trendline
Ascletis Reports Superior Weight Loss Results for ASC37 in Obese Mouse Model

Ascletis Reports Superior Weight Loss Results for ASC37 in Obese Mouse Model

Ascletis Reports Superior Weight Loss Results for ASC37 in Obese Mouse Model
Trendline Trendline
Alkermes Reports Break-Even Q2 Earnings, Revenue Surpasses Estimates

Alkermes Reports Break-Even Q2 Earnings, Revenue Surpasses Estimates

Alkermes Reports Break-Even Q2 Earnings, Revenue Surpasses Estimates
Reuters Reuters
S&P 500 inches higher in choppy trading as investors await pivotal earnings

S&P 500 inches higher in choppy trading as investors await pivotal earnings

By Johann M Cherian and Ragini Mathur July 28 (Reuters) - The benchmark S&P 500 edged higher in a choppy session on Tuesday, as gains in other sectors offset a decline in chip stocks ahead of key earnings reports from some of Wall Street's "Magnificent Seven" companies.
Reuters Reuters
GSK launches $2.5 billion savings drive to fund faster drug development

GSK launches $2.5 billion savings drive to fund faster drug development

By Bhanvi Satija and Raechel Thankam Job LONDON, July 28 (Reuters) - GSK launched a £1.9 billion ($2.52 billion) cost-savings effort on Tuesday to help fund the British drugmaker's expanded late-stage study roster, as CEO Luke Miels works to deliver on his promise of faster drug development.
Trendline Trendline
Israeli Business Group Urges Local IPOs for Defense Giants Amid Global Demand

Israeli Business Group Urges Local IPOs for Defense Giants Amid Global Demand

Israeli Business Group Urges Local IPOs for Defense Giants Amid Global Demand
Trendline Trendline
Kiniksa Pharmaceuticals' IL 1 Franchise Expansion Boosts Earnings Forecast

Kiniksa Pharmaceuticals' IL 1 Franchise Expansion Boosts Earnings Forecast

Kiniksa Pharmaceuticals' IL 1 Franchise Expansion Boosts Earnings Forecast